Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04716452 · ClinicalTrials.gov registry record · Phase 1
Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1 study of Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory, sponsored by Keystone Nano.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT04716452 is a Phase 1 study of Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory that is actively recruiting participants, run by Keystone Nano. The registered enrollment target is 15 participants, below the 59-participant average among 16 other Acute Myeloid Leukemia, in Relapse trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04716452, a Phase 1 study of Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory, is actively recruiting participants, sponsored by Keystone Nano.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The study objective is to evaluate patient safety for patients with refractory and relapsed AML being treated with Ceramide NanoLiposome (CNL) .
Conditions Studied
Interventions
- DRUG Ceramide NanoLiposome (Ceraxa)
Study Locations (1)
Virginia
- University of Virginia Cancer Center - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2026-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04716452
The ClinicalTrials.gov registry entry for NCT04716452 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 59-participant average among 16 other Acute Myeloid Leukemia, in Relapse trials with a reported enrollment target (75% lower). The listed sponsor is Keystone Nano, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Acute Myeloid Leukemia, in Relapse appearing as the primary indexed condition, and to 1 intervention - of which Ceramide NanoLiposome (Ceraxa) is the first listed.
NCT04716452 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT04716452 about?
NCT04716452 is a clinical study titled "Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia". The study objective is to evaluate patient safety for patients with refractory and relapsed AML being treated with Ceramide NanoLiposome (CNL) .
What is the current status of trial NCT04716452?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2025-10-01. Estimated completion is 2026-11-30.
What conditions does trial NCT04716452 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, Refractory/Relapse Acute Myeloid Leukemia.
What interventions are being tested in trial NCT04716452?
The interventions under investigation include: Ceramide NanoLiposome (Ceraxa) (DRUG).
Who is sponsoring clinical trial NCT04716452?
This trial is sponsored by Keystone Nano, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04716452 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia, in Relapse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia
RECRUITING · Phase 1
-
PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML
RECRUITING · Phase 1
-
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
RECRUITING · Phase 1
-
Venetoclax to Augment Epigenetic Modification and Chemotherapy
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RECRUITING · Phase 1
Explore more on PlainTrial
Acute Myeloid Leukemia, in Relapse
All registered trials for this condition
Acute Myeloid Leukemia Refractory
All registered trials for this condition
Virginia
All trials with a study site in Virginia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.